Apotex Moves To Block Coherus' Neulasta Biosimilar; Asks FDA To Require Patient Studies

Apotex argues that biosimilar studies in healthy volunteers are not sufficient to show clinically meaningful differences with the reference product; Coherus says it believes its application is scientifically sound.

Three weeks before FDA is to take action on Coherus BioSciences Inc.'s Neulasta (pegfilgrastim) biosimilar application, Apotex Inc. has asked the agency to require all pegfilgrastim sponsors to conduct studies in the intended patient population, not just in healthy volunteers.

In an April 21 citizen petition, Apotex says FDA should require biosimilar sponsors referencing Amgen Inc.'s Neulasta...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics